| Sep 5 |
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
|
| Sep 4 |
Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
|
| Aug 29 |
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
|
| Aug 13 |
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
|
| Aug 9 |
Apellis: Rare Kidney Disease Data Leads To Possible First To Market
|
| Aug 9 |
Sobi and Apellis report positive topline results from Phase III pegcetacoplan study
|
| Aug 8 |
Apellis plans FDA filing after drug success in kidney trial
|
| Aug 8 |
Apellis stock jumps as rare kidney disease therapy succeeds in trial
|
| Aug 8 |
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
|
| Aug 8 |
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
|
